Galapagos « Terug naar discussie overzicht

GLPG1205 en GLPG1690

474 Posts, Pagina: « 1 2 3 4 5 6 ... 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 » | Laatste

Omlaag ↓

Wall Street Trader 15 juli 2020 11:12

@lmr Gilead and Galapagos are using that compound name for more than a year now ;-)

pubchem.ncbi.nlm.nih.gov/compound/904...

www.deaandeelhouder.nl/nieuws/2020/01...

ml-eu.globenewswire.com/Resource/Down...

reports.glpg.com/2020/q1/nl/de-galapa...

Crees 15 juli 2020 12:00

Vraagje, begrijp ik het goed dat GLPG1690 potentieel kan worden ingezet als medicijn om Covid-19 patienten sneller/beter te laten recoveren na longschade? Mss zelfs tijdens het ondergaan van Covid-19 ziekte schade aan longen beperken? thx !

Wall Street Trader 16 juli 2020 22:29

Ziritaxestat

For idiopathic pulmonary fibrosis (IPF)

IPF $2.8B market with large unmet needs

Systemic sclerosis (SSc)

Fully recruited, topline data expected in H2,
orphan status in SSc in US and EC

Bijlage:

[verwijderd] 29 juli 2020 10:12

Notulen PDCO-vergadering eind februari 2020 met bespreking GLPG1690 voor kinderziekten.

2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-
methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-fluorophenyl)-1,3-thiazole5-carbonitrile (GLPG1690) - Orphan - EMEA-002333-PIP02-19

Galapagos NV; Treatment of interstitial pulmonary diseases with fibrosis
Day 120 opinion
Pneumology – Allergology

Summary of committee discussion:
The committee’s views expressed on day 90 were re-discussed and endorsed.
Based on the assessment of this application and further discussions at the Paediatric
Committee, the PDCO adopted a positive opinion.

www.ema.europa.eu/en/documents/minute...

Pneumology covers a spectrum of acute and chronic conditions affecting the airways, including the lungs, pulmonary vessels, pleura, chest wall, respiratory support muscles and the central respiratory command.
www.hfh.com.vn/en/181/pneumology-alle...

GLPG1690 is onderwerp van gesprek binnen PDCO-commissie: toekomstige kinder-onderzoeken..? Zie onderstaand wat valt onder Pneumologie.

"chronische aandoeningen van de luchtwegen, waaronder de longen, longvaten, borstvlies, borstwand, ademhalingsondersteunende spieren en de centrale ademhalingsopdracht". Of allergische ziekten.

Lama Daila 31 juli 2020 09:38

Dit is het draadje voor GLPG1205 en GLPG1690, maar wat doen we dan met de nieuwe IPF-compounds: GLPG4124, GLPG3535, GLPG4586, GLPG4605 (Zie recentste slide GILD-pipeline)?
GLPG3535 had ik niet direct verwacht in het lijstje van Fibrosis. Dit was de compound met ASK1-inhibitor (Pain, Calchan).

Stafke 31 juli 2020 11:04

Mij lijkt het beter een fibrosis draadje te openen.
De eer hiervoor komt toe aan onze specialist(en) ter zake.

[verwijderd] 1 augustus 2020 11:18

Mooie signalen voor Ziritaxestat (1690) vanuit de patiënten populatie Ph3 IPF.

www.inspire.com/groups/living-with-pu...

Kopie stukje tekst:
I have been participating in the trial since June 2019. I have been taking Esbriet (since 2017) along with the "study drug". Since it is a blind study, I do not know for sure whether I am on the drug. However, my PFT & 6-minute walk test results have been stable or slightly improved over the last 13 months, and I just had a CT scan through my regular pulmonologist indicating stable fibrosis over that period. I have had little in the way of side effects while on the study drug. Based on my experience, I highly recommend the study. Good luck to you.

(Einde kopie)

—> Leuk om te lezen, zowel voor de patiënten als voor beleggers!
En er zijn er nog die positieve reacties uiten, met bovendien weinig bijwerkingen.

[verwijderd] 1 augustus 2020 11:51

En nog eentje, in verband met opvolging van de studie tijdens Corona pandemie waarbij een patiënt het volgende verklaarde:

I am still in the Galapagos study - entering my twelfth month. I have had a telemedicine call with my pulmonologist and, at this point, he doesn't know whether the trial will continue for us in an "open label" way once we complete the full twelve months. He has contacted the trial developers but as far as I know, nothing has been decided.

One issue under discussion last month was how to get the meds to participants beyond the trial length. I have not had any additional symptoms either (on Esbriet) but according to my doctor, that doesn't really mean anything as no one seems to be having side effects. I have also been stable since the trial began for me in May 2019

Prachtig toch?!

Wall Street Trader 1 augustus 2020 14:05

A novel LC-MS/MS method for the determination of ziritaxestat in rat plasma and its pharmacokinetic study

Ziritaxestat is a first-in-class autotoxin inhibitor. The purpose of this study was to develop a liquid chromatography/electrospray ionization tandem mass spectrometric (LC-MS/MS) method for the determination of ziritaxestat in rat plasma.

The validated LC-MS/MS method was successfully applied to study the pharmacokinetic profiles of ziritaxestat in rat plasma after intravenous and oral administration. Pharmacokinetic results demonstrated that ziritaxestat displayed a short half-life (~3 h) and low bioavailability (20.52%).

pubmed.ncbi.nlm.nih.gov/32329073/

Benzoxaboroles-Novel Autotaxin Inhibitors

Abstract

Autotaxin (ATX) is an extracellular enzyme that hydrolyses lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA), which has a role in the mediation of inflammation, fibrosis and cancer. ATX is a drug target that has been the focus of many research groups during the last ten years. To date, only one molecule, Ziritaxestat (GLPG1690) has entered the clinic; it is currently in Phase 3 clinical trials for idiopathic pulmonary fibrosis. Other small molecules, with different binding modes, have been investigated as ATX inhibitors for cancer including compounds possessing a boronic acid motif such as HA155.

pubmed.ncbi.nlm.nih.gov/31547058/

aossa 1 augustus 2020 15:21

:-)

Stapvoets 1 augustus 2020 16:53

[quote alias=Barbet01 id=12617558 date=202008011151]
En nog eentje, in verband met opvolging van de studie tijdens Corona pandemie waarbij een patiënt het volgende verklaarde:

I am still in the Galapagos study - entering my twelfth month. I have had a telemedicine call with my pulmonologist and, at this point, he doesn't know whether the trial will continue for us in an "open label" way once we complete the full twelve months. He has contacted the trial developers but as far as I know, nothing has been decided.

One issue under discussion last month was how to get the meds to participants beyond the trial length. I have not had any additional symptoms either (on Esbriet) but according to my doctor, that doesn't really mean anything as no one seems to be having side effects. I have also been stable since the trial began for me in May 2019

Prachtig toch?!

Super!! Rotziekte en als dit dan het effect kan zijn.

Wall Street Trader 5 augustus 2020 14:38

The American Thoracic Society's Virtual Conference 2020 kicks-off today.
Both Galapagos & Gilead are attending the event.

ATS 2020 | VIRTUAL Programs

ISABELA - how to execute the largest Phase 3 program in IPF to date

conference.thoracic.org/program/index...

Bijlage:

Lama Daila 8 augustus 2020 10:26

conference.thoracic.org/program/virtu...

Wednesday, August 5

ISABELA - how to execute the largest Phase 3 program in IPF to date
Sponsored by Gilead Sciences & Galapagos
On-Demand, 1 - 1:30 p.m. EDT | Open to all attendees
Topic: Idiopathic Pulmonary Fibrosis (IPF)

The ISABELA clinical trial programe is planned to be the largest phase 3 programme performed in patients with IPF to date, globally recruiting 1,500 patients in a rare disease population. This presentation will showcase the innovative and agile ways in which Galapagos have responded to the needs of patients and investigators to ensure the successful execution of these trials.

Speaker:
Paul Ford, MD PhD, Galapagos

Wall Street Trader 8 augustus 2020 16:22

ATS2020 ePoster from Galapagos and Gilead.

We developed an algorithm to adjudicate acute respiratory events in the ISABELA IPF phase 3 trials. We hope to make reporting consistent and comparable in the future so we can cure IPF.

cattendee.abstractsonline.com/meeting...

Bijlage:

harvester 26 augustus 2020 10:35

Zie persrelease van vandaag.

De presentaties door Galapagos op ERS conferentie, bevatten info over 1205 studie en highlights over de fase 3 studie in 1690.

Dus iets om naar uit te kijken!

Wall Street Trader 26 augustus 2020 11:23

Galapagos presenteert nieuwe inzichten in IPF en gerelateerde klinische ontwikkelingen op het European Respiratory Society Congress

ml-eu.globenewswire.com/Resource/Down...

Op woensdag 9 september 2020 zal Galapagos samen met het EU-IPFF gastheer zijn voor het
eerste virtueel symposium ooit geleid door een patiëntenorganisatie, getiteld ‘Improving pulmonary fibrosis diagnosis and care in Europe’. Onderwerpen zoals de beleving van de patiënt en de belangrijkste onvervulde behoeftes zullen worden besproken, alsook de toegang tot de zorg in IPF door heel Europa. Aansluitend wordt er een nieuw educatief programma over het herkennen van longfibrose voor huisartsen gepresenteerd.

Virtual ERS International Congress 2020: access abstracts, e-posters and pre-recorded content.

A variety of pre-Congress content is now available on the virtual ERS International Congress platform. The content can be accessed by all and offers a taste of what’s to come in the exciting live programme on 7–9 September.

www.ersnet.org/the-society/news/virtu...

www.youtube.com/watch?v=CS6hbtdHT04

Wall Street Trader 26 augustus 2020 13:13

Improving pulmonary fibrosis diagnosis and care in Europe

Galapagos & European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF)
Organized by : Galapagos & European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF)

E-posters and Program

Bijlage:

[verwijderd] 26 augustus 2020 20:53

Mij viel in het pb deze ochtend op dat Pinta expliciet vermeld werd ?
Vreemd want de studie staat zelfs nog niet op completed

Camul 26 augustus 2020 22:34

quote:
Toert schreef op 26 augustus 2020 20:53:
Mij viel in het pb deze ochtend op dat Pinta expliciet vermeld werd ?
Vreemd want de studie staat zelfs nog niet op completed

PINTA / GLPG1205
Actual Primary Completion Date : July 21, 2020
Estimated Study Completion Date : August 2020

Er zullen ongetwijfeld al resultaten binnenkomen, in september weten we meer!

[verwijderd] 26 augustus 2020 23:43

quote:
Camul schreef op 26 augustus 2020 22:34:
[...]

PINTA / GLPG1205
Actual Primary Completion Date : July 21, 2020
Estimated Study Completion Date : August 2020

Er zullen ongetwijfeld al resultaten binnenkomen, in september weten we meer!

En toch vind ik het vreemd. Normaal duurt het een tweetal maanden na de completed.

Misschien zeggen ze enkel iets over het opzetten van de studie ?

474 Posts, Pagina: « 1 2 3 4 5 6 ... 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	19 apr 2024 17:35
Koers	27,180
Verschil	-0,200 (-0,73%)
Hoog	27,280
Laag	26,860
Volume	62.640
Volume gemiddeld	81.069
Volume gisteren	135.801

Galapagos nieuws

12 apr	KBC Securities verlaagt koersdoel Gal...
05 apr	Galapagos toont innovatieve aanpak in...
23 feb	AEX op de waakvlam het weekend in, ko...	2
23 feb	Beursblik: gebrek aan opwaarts potent...
23 feb	Gaat AEX op recordjacht of gaat de be...
23 feb	Update : Galapagos voldoet aan verwac...
19 feb	Beursblik: cashburn belangrijk voor G...
15 feb	Galapagos presenteert nieuwe onderzoe...
01 feb	Galapagos rondt Jyseleca-transactie af
04 jan	Galapagos in zee met Thermo Fisher

Meer ››